Breaking News, Collaborations & Alliances

Halozyme Therapeutics, argenx Expand Global Collaboration & License Agreement

argenx has nominated 4 additional targets, expanding its exclusive access to Halozyme’s ENHANZE drug delivery technology.

Author Image

By: Charlie Sternberg

Associate Editor

Halozyme Therapeutics Inc. today announced that argenx has nominated four additional targets under their existing global collaboration and license agreement. This expands argenx’s exclusive access to Halozyme’s ENHANZE drug delivery technology, a proprietary recombinant human hyaluronidase enzyme for rapid subcutaneous drug delivery.   With the addition of these new targets, argenx now has exclusive rights to ENHANZE for a total of six programs, including its approved FcRn blocker, VYVGART Hyt...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters